FDA grants Orphan Drug status for Shift’s lead compound for SMA
FDA grants Orphan Drug status for Shift’s lead compound for SMA
May 14, 2020
Steve Oconnor
Shift’s E1V1.11 drug compound to treat Spinal Muscular Atrophy (SMA) granted Orphan Drug Status by FDA.
Overland Park: The Food and Drug Administration (FDA) granted orphan drug designation for Shift Pharmaceutical’s lead drug compound to treat all forms of spinal muscular atrophy (SMA). Orphan Drug Status provides incentives for companies to research drug developments to treat rare diseases such as SMA.
